search
Back to results

Multiple Sessions of Transcranial Direct Current Stimulation in People With Parkinson's Disease

Primary Purpose

Parkinson Disease, Healthy Adult

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cerebellar transcranial direct current stimulation at 4 mA
Sham cerebellar transcranial direct current stimulation
Sponsored by
University of Iowa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring transcranial direct current stimulation, cerebellum, gait, balance, cognition, fatigue

Eligibility Criteria

50 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

To be eligible to participate in this study, people with PD must meet the following criteria:

  1. Adult (50-90 yrs) with a positive diagnosis of Parkinson's disease from a movement disorder specialist
  2. On an unchanged regimen of dopaminergic medication for at least the last 3 months
  3. Able to independently walk for 6 min
  4. Without other severe chronic psychiatric or medical conditions
  5. Not taking any psychoactive medications

To be eligible to participate in this study, the NH subjects must meet the following criteria:

  1. Adult (50-90 yrs)
  2. Able to independently walk for 6 min
  3. Without any severe chronic psychiatric or medical conditions
  4. Not taking any psychoactive medications

Exclusion Criteria:

An individual from either group who meets any of the following criteria will be excluded from participation in this study:

  1. Pregnant
  2. Known holes or fissures in the skull
  3. Metallic objects or implanted devices in the skull/head (e.g., metal plate, deep brain stimulator)
  4. Current or previous injuries or surgeries that cause unusual gait
  5. A score less than 24 or 17 on the Montreal Cognitive Assessment (MoCA) or telephone-MoCA, respectively

Additional exclusion for PwPD:

  1. Experience freezing of gait
  2. A diagnosis of dementia or other neurodegenerative diseases

Additional exclusion for NH subjects:

1. A diagnosis of dementia or any neurodegenerative diseases

Sites / Locations

  • University of Iowa

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Sham Comparator

Active Comparator

Sham Comparator

Arm Label

PD-ctDCS

PD-sham

NH-ctDCS

NH-sham

Arm Description

People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.

People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.

Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.

Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.

Outcomes

Primary Outcome Measures

Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPRDS)
The scale includes four parts that assess activities of daily living (Parts I and II), a motor exam (Part III), and medication-related motor complications (Part IV). For all parts, a higher number indicates more disability.
Fatigue Severity Scale (FSS)
A nine-item questionnaire asking subjects to rate the severity of their perceived fatigue on a 1-7 point Likert scale (a higher number means more subjective fatigue).
Multidimensional Fatigue Inventory (MFI)
A 20-item scale evaluating five dimensions of fatigue rated on a 1-5 point Likert scale (positively phrase items reverse scored; a higher number means more fatigue).
30-meter walk test, single-task (30mWT-ST; 2 trials)
Subjects walk at their usual/comfortable speed; walking characteristics and the time taken to complete the task are the primary outcomes (more time = worse performance)
30-meter walk test, dual-task (30mWT-DT; 2 trials)
Same as 30mWT-ST, except the subjects perform a secondary/cognitive task during the walking. The secondary task will involve serially subtracting 7 from a randomly selected starting number (100, 125, 150, 200; won't repeat a starting number within a given session). Changes in task performance between single- and dual-task conditions represent dual-task interference.
6-minute walk test (6MWT; 1 trial)
Subjects walk back and forth between two markers spaced 30 m apart at the usual speed. The total distance walked is the primary outcome (longer distance walked is an analog for less fatigue).
9-hole peg test (9-HPT; two trials with each hand)
The subjects are instructed to pick up the pegs from a shallow cup one at a time, place them in the holes, and then immediately take the pegs back out of the holes one at a time. Time to put the pegs in and take them out again is recorded (more time = worse performance).
Reaction time test (simple and choice; 1 trial each)
Simple: A white box is displayed on a computer screen. When a black X appears in the white box, the subjects need to press the computer space bar as quickly as possible. Several trials with random inter-stimulus-intervals are presented. Choice: Four white boxes are displayed on the screen. When a black X appears in one of the boxes, the subjects need to press the appropriate key (z = left-most box, x = second from left, comma (,) = third from left, and period (.) = right-most) as quickly as possible. The average reaction time is recorded (more time = worse performance).
Flanker Inhibitory Control and Attention Test (1 trial)
On each trial, a central directional target (arrow) is flanked by similar stimuli on the left and right (five total arrows). The task is to indicate the direction of the central stimulus (i.e., the third arrow). On congruent trials, the flanker arrows face the same direction as the target. On incongruent trials, they face the opposite direction. Time to react to the different conditions is recorded (more time = worse performance).
Trail Making Test A and B (TMT A/B; 1 trial each)
Both parts consist of 25 circles (Part A: numbered 1 - 15; Part B: numbers and letters 1- 13 and A - L). The subject draws lines connecting the numbers in ascending order (Part A: 1-2-3-4-5 etc.) and then in alternating-ascending order (Part B; e.g., 1-A-2-B-3-C, etc.) as quickly and as accurately as possible without lifting the pen/pencil off the paper. Time to complete the "trail" is recorded (more time = worse performance).
Berg Balance Scale (BBS)
14-item scale rated on a 0 - 4 Likert scale that assesses balance performance in several dynamic and static conditions (lower score = worse balance).
Static Posturography.
1) stand on a firm surface (directly on a force platform) for 1 minute with eyes open (balance characteristics [95% confidence interval of the total 2D area explored, the center of pressure movement velocity in forward/backward and left/right directions] are the primary outcomes), 2) stand on a foam surface (6 cm foam pad placed on top of force platform) for 1 minute with eyes open (the same balance characteristics as above are the primary outcomes).

Secondary Outcome Measures

Brain activity PET Imaging with [18F]Fluorodeoxyglucose (FDG)
Assesses resting-state brain activity by determining brain glucose usage. Involves the injection of a radioactive glucose analog that can be imaged with the PET scanner.

Full Information

First Posted
February 16, 2021
Last Updated
June 21, 2022
Sponsor
University of Iowa
search

1. Study Identification

Unique Protocol Identification Number
NCT04762823
Brief Title
Multiple Sessions of Transcranial Direct Current Stimulation in People With Parkinson's Disease
Official Title
Multiple Sessions of Transcranial Direct Current Stimulation in People With Parkinson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Withdrawn
Why Stopped
The PI (Post-Doc Craig Workman) left the university.
Study Start Date
August 15, 2021 (Anticipated)
Primary Completion Date
January 1, 2022 (Anticipated)
Study Completion Date
January 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Iowa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Parkinson's disease (PD) affects approximately 1 million people in the US, with annual health care costs approaching $11 billion. PD results from a loss of dopamine-producing cells in the brain. This decrease in dopamine is associated with shaking, stiffness, slowness, balance/walking problems, thinking, and fatigue which severely impair activities of daily living. Current medical and surgical treatments for PD are either only mildly effective, expensive, or associated with a variety of side-effects. Therefore, the development of practical and effective therapies would have significant benefits. Transcranial direct current stimulation (tDCS) can influence how the brain works. A review of studies concluded that, overall, tDCS improves walking and balance in people with PD (PwPD). However, these studies had mixed results. For example, most have stimulated the frontal brain areas and all have used intensities of 2 mA (milliamperes; a measure of electrical current strength) or less. However, given the vital role of the cerebellum in walking and balance, and in PD impairments, the cerebellum may represent a more effective brain target. A recent review of studies also recommended performing investigations of higher intensity tDCS (greater than 2 mA), to potentially increase stimulation efficacy. No study has investigated the effects of multiple sessions of cerebellar tDCS on gait and balance in PwPD and none have used tDCS intensities greater than 2 mA. Therefore, there is a critical need to determine if repeated sessions of cerebellar tDCS might improve walking and balance in the short- and long-term.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Healthy Adult
Keywords
transcranial direct current stimulation, cerebellum, gait, balance, cognition, fatigue

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Subjects will be blind to the different stimulation intensities (sham, 4 mA) and the test administrators will also be blind to the subject's assigned stimulation condition.
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PD-ctDCS
Arm Type
Experimental
Arm Description
People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
Arm Title
PD-sham
Arm Type
Sham Comparator
Arm Description
People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
Arm Title
NH-ctDCS
Arm Type
Active Comparator
Arm Description
Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
Arm Title
NH-sham
Arm Type
Sham Comparator
Arm Description
Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
Intervention Type
Device
Intervention Name(s)
Cerebellar transcranial direct current stimulation at 4 mA
Other Intervention Name(s)
ctDCS
Intervention Description
Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Intervention Type
Device
Intervention Name(s)
Sham cerebellar transcranial direct current stimulation
Other Intervention Name(s)
Sham
Intervention Description
Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
Primary Outcome Measure Information:
Title
Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPRDS)
Description
The scale includes four parts that assess activities of daily living (Parts I and II), a motor exam (Part III), and medication-related motor complications (Part IV). For all parts, a higher number indicates more disability.
Time Frame
Through study completion, up to 12 months
Title
Fatigue Severity Scale (FSS)
Description
A nine-item questionnaire asking subjects to rate the severity of their perceived fatigue on a 1-7 point Likert scale (a higher number means more subjective fatigue).
Time Frame
Through study completion, up to 12 months
Title
Multidimensional Fatigue Inventory (MFI)
Description
A 20-item scale evaluating five dimensions of fatigue rated on a 1-5 point Likert scale (positively phrase items reverse scored; a higher number means more fatigue).
Time Frame
Through study completion, up to 12 months
Title
30-meter walk test, single-task (30mWT-ST; 2 trials)
Description
Subjects walk at their usual/comfortable speed; walking characteristics and the time taken to complete the task are the primary outcomes (more time = worse performance)
Time Frame
Through study completion, up to 12 months
Title
30-meter walk test, dual-task (30mWT-DT; 2 trials)
Description
Same as 30mWT-ST, except the subjects perform a secondary/cognitive task during the walking. The secondary task will involve serially subtracting 7 from a randomly selected starting number (100, 125, 150, 200; won't repeat a starting number within a given session). Changes in task performance between single- and dual-task conditions represent dual-task interference.
Time Frame
Through study completion, up to 12 months
Title
6-minute walk test (6MWT; 1 trial)
Description
Subjects walk back and forth between two markers spaced 30 m apart at the usual speed. The total distance walked is the primary outcome (longer distance walked is an analog for less fatigue).
Time Frame
Through study completion, up to 12 months
Title
9-hole peg test (9-HPT; two trials with each hand)
Description
The subjects are instructed to pick up the pegs from a shallow cup one at a time, place them in the holes, and then immediately take the pegs back out of the holes one at a time. Time to put the pegs in and take them out again is recorded (more time = worse performance).
Time Frame
Through study completion, up to 12 months
Title
Reaction time test (simple and choice; 1 trial each)
Description
Simple: A white box is displayed on a computer screen. When a black X appears in the white box, the subjects need to press the computer space bar as quickly as possible. Several trials with random inter-stimulus-intervals are presented. Choice: Four white boxes are displayed on the screen. When a black X appears in one of the boxes, the subjects need to press the appropriate key (z = left-most box, x = second from left, comma (,) = third from left, and period (.) = right-most) as quickly as possible. The average reaction time is recorded (more time = worse performance).
Time Frame
Through study completion, up to 12 months
Title
Flanker Inhibitory Control and Attention Test (1 trial)
Description
On each trial, a central directional target (arrow) is flanked by similar stimuli on the left and right (five total arrows). The task is to indicate the direction of the central stimulus (i.e., the third arrow). On congruent trials, the flanker arrows face the same direction as the target. On incongruent trials, they face the opposite direction. Time to react to the different conditions is recorded (more time = worse performance).
Time Frame
Through study completion, up to 12 months
Title
Trail Making Test A and B (TMT A/B; 1 trial each)
Description
Both parts consist of 25 circles (Part A: numbered 1 - 15; Part B: numbers and letters 1- 13 and A - L). The subject draws lines connecting the numbers in ascending order (Part A: 1-2-3-4-5 etc.) and then in alternating-ascending order (Part B; e.g., 1-A-2-B-3-C, etc.) as quickly and as accurately as possible without lifting the pen/pencil off the paper. Time to complete the "trail" is recorded (more time = worse performance).
Time Frame
Through study completion, up to 12 months
Title
Berg Balance Scale (BBS)
Description
14-item scale rated on a 0 - 4 Likert scale that assesses balance performance in several dynamic and static conditions (lower score = worse balance).
Time Frame
Through study completion, up to 12 months
Title
Static Posturography.
Description
1) stand on a firm surface (directly on a force platform) for 1 minute with eyes open (balance characteristics [95% confidence interval of the total 2D area explored, the center of pressure movement velocity in forward/backward and left/right directions] are the primary outcomes), 2) stand on a foam surface (6 cm foam pad placed on top of force platform) for 1 minute with eyes open (the same balance characteristics as above are the primary outcomes).
Time Frame
Through study completion, up to 12 months
Secondary Outcome Measure Information:
Title
Brain activity PET Imaging with [18F]Fluorodeoxyglucose (FDG)
Description
Assesses resting-state brain activity by determining brain glucose usage. Involves the injection of a radioactive glucose analog that can be imaged with the PET scanner.
Time Frame
Through study completion, up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: To be eligible to participate in this study, people with PD must meet the following criteria: Adult (50-90 yrs) with a positive diagnosis of Parkinson's disease from a movement disorder specialist On an unchanged regimen of dopaminergic medication for at least the last 3 months Able to independently walk for 6 min Without other severe chronic psychiatric or medical conditions Not taking any psychoactive medications To be eligible to participate in this study, the NH subjects must meet the following criteria: Adult (50-90 yrs) Able to independently walk for 6 min Without any severe chronic psychiatric or medical conditions Not taking any psychoactive medications Exclusion Criteria: An individual from either group who meets any of the following criteria will be excluded from participation in this study: Pregnant Known holes or fissures in the skull Metallic objects or implanted devices in the skull/head (e.g., metal plate, deep brain stimulator) Current or previous injuries or surgeries that cause unusual gait A score less than 24 or 17 on the Montreal Cognitive Assessment (MoCA) or telephone-MoCA, respectively Additional exclusion for PwPD: Experience freezing of gait A diagnosis of dementia or other neurodegenerative diseases Additional exclusion for NH subjects: 1. A diagnosis of dementia or any neurodegenerative diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Craig D Workman, PhD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Multiple Sessions of Transcranial Direct Current Stimulation in People With Parkinson's Disease

We'll reach out to this number within 24 hrs